Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
about
Tim-3 and Tim-4 as the potential targets for antitumor therapyBlocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune response4-1BB Agonists: Multi-Potent Potentiators of Tumor ImmunityTumor infiltrating lymphocytes in ovarian cancerRole of TIM-3 in ovarian cancer.Minireview: Regulatory T Cells and Ovarian Cancer.Tim-3 and its role in regulating anti-tumor immunity.Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.Immunotherapy for ovarian cancer.Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer.Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.Combination cancer immunotherapies tailored to the tumour microenvironment.Combined Blockade of T Cell Immunoglobulin and Mucin Domain 3 and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Results in Durable Therapeutic Efficacy in Mice with Intracranial Gliomas.The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas.Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.Preferential Tim-3 expression on Treg and CD8(+) T cells, supported by tumor-associated macrophages, is associated with worse prognosis in gastric cancer.Immuno-oncology combinations: raising the tail of the survival curve.New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models.Immune regulation by Tim-3.Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions.Tim-3 expression and its role in hepatocellular carcinomaTIM-3, a promising target for cancer immunotherapy
P2860
Q26799502-B83FCC03-E99C-4772-99B2-20541B0A7D13Q26863081-89C4B742-04F8-4349-A759-A813F64AB780Q27012963-605D7ED2-599E-43EB-BE6F-7B32236F66EAQ27021878-F8DE5B6A-CB53-4CF6-BFB4-050EAA17E645Q30235023-E60A2C92-9BB7-4FAA-B11E-C70A4FC8D3E5Q30244214-E6D4163A-630A-4C71-BB0D-794CCADD61D4Q33909020-62B349D3-0A17-4129-A972-CEE5E2B5E8FDQ33926200-DEA6473B-34FA-4984-AF47-4E46809C6C7CQ34022694-03A4890E-3712-476E-8A8B-C0A82CAEC349Q35107110-0B38B571-E8A2-446B-85CE-81CFF103710BQ35164189-FFCF6579-9636-476A-90EC-EFB278790FC3Q35896426-FCDC74AF-84BC-41D1-9CEF-3A31073B5074Q36797398-59CAB5FB-F931-4A7B-9DE4-6108C2B50E7CQ38198735-C34E81DC-9B7A-426C-9B4D-83CFB5EF23FCQ38440279-84A1C2A3-8CD8-4EA8-9D4C-F506B4A33C0FQ38645178-5648A1AF-AB40-47AE-A416-9746917D9DB9Q38665664-E29D4AE5-B7E0-433C-B92A-4A10707E2ABCQ38666253-25FEFC44-050F-491D-A8B1-E897927883FDQ38760734-4482A29D-24C2-42E7-99D1-966F599D6D88Q38770814-30914B44-6F62-4B79-8241-D0DCECA0434DQ39371916-B8252A08-59FC-4E87-99A9-83CDF267FA08Q42421273-68B8A860-0DF3-4336-BFB2-C245B3CC68E6Q46047154-4015CC7C-42E4-4270-9437-A4A97394D7C6Q47399053-E1051A6F-718A-45B6-A31B-04F68DC82EA3Q47820348-61FFE568-311C-4DDE-8E37-5628138844ACQ49737040-1FF2BA14-014C-4A3F-ACF3-0CFC652DF40FQ52348457-7F02DFCD-F903-4496-A653-F9D891175261Q55285607-F5435C79-90DE-4DED-BE5B-B97538958911Q57476217-A0A67A9C-A856-4C4D-B65C-C70D64CEEF4AQ58558279-0D774B16-BEF3-4B63-9548-72506039BEE9
P2860
Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combined TIM-3 blockade and CD ...... urine model of ovarian cancer.
@en
Combined TIM-3 blockade and CD ...... urine model of ovarian cancer.
@nl
type
label
Combined TIM-3 blockade and CD ...... urine model of ovarian cancer.
@en
Combined TIM-3 blockade and CD ...... urine model of ovarian cancer.
@nl
prefLabel
Combined TIM-3 blockade and CD ...... urine model of ovarian cancer.
@en
Combined TIM-3 blockade and CD ...... urine model of ovarian cancer.
@nl
P2093
P2860
P356
P1476
Combined TIM-3 blockade and CD ...... urine model of ovarian cancer.
@en
P2093
Dali Cheng
Liangliang Wu
Shulan Zhang
Zhijun Xia
Zhiqiang Guo
P2860
P2888
P356
10.1186/1479-5876-11-215
P577
2013-09-17T00:00:00Z
P5875
P6179
1010480224